Volume 100, Issue 4 pp. 233-239

Effects of Thalidomide on Isoprenaline-Induced Acute Myocardial Injury: A Haemodynamic, Histopathological and Ultrastructural Study

Harish K. Loh

Harish K. Loh

Departments of Pharmacology,

Search for more papers by this author
Kanhei C. Sahoo

Kanhei C. Sahoo

Departments of Pharmacology,

Search for more papers by this author
Kamal Kishore

Kamal Kishore

Departments of Pharmacology,

Search for more papers by this author
Ruma RayTapas C. Nag

Tapas C. Nag

Anatomy, All India Institute of Medical Sciences, New Delhi, and

Search for more papers by this author
Santosh Kumari

Santosh Kumari

Division of Plant Physiology, Indian Agricultural Research Institute, New Delhi, India

Search for more papers by this author
Dharamvir S. Arya

Dharamvir S. Arya

Departments of Pharmacology,

Search for more papers by this author
First published: 15 March 2007
Citations: 26
Author for correspondence: Dharamvir S. Arya, Cardiovascular Laboratory, Department of Pharmacology, All India Institute of Medical Sciences, New Delhi-110 029, India (fax +91-11-26588641, e-mail [email protected]).

Abstract

Abstract: In the present study, we investigated the cardioprotective effects of thalidomide in a rat model of acute myocardial injury, induced by subcutaneous injection of isoprenaline hemisulphate (85 mg/kg per day for 2 days). Thalidomide (75/150/300 mg/kg) or vehicle (dimethylsulphoxide) or saline (0.9% NaCl) was administered orally for 14 days and isoprenaline injection on the 12th and 13th days. Cardiovascular responses (arterial and left ventricular haemodynamic parameters and heart rate) were obtained in anaesthetized rats on the 14th day. Histopathological and electronmicroscopical analysis of myocardial injury was done. The results showed that thalidomide 300 mg/kg per day orally caused significant improvement in isoprenaline-induced reduction of cardiac function with increases in maximum rate of pressure development (+LVdP/dt, P < 0.001) and maximum rate of pressure decline (–LVdP/dt, P < 0.001) and decreases in left ventricular end-diastolic pressure (P < 0.01), systolic arterial pressure (P < 0.001), diastolic arterial pressure (P < 0.001), mean arterial pressure (P < 0.001) and heart rate (P < 0.001). The myocardial injury caused by isoprenaline was significantly reduced by thalidomide treatment as judged by the reduction of myocardial necrosis, ultrastructural changes such as mitochondria and myofibril damage, 300 mg/kg being the most effective dose. In conclusion, oral administration of thalidomide is able to ameliorate isoprenaline-induced myocardial injury and impaired myocardial function in spite of decreases in systolic arterial pressure, diastolic arterial pressure and mean arterial pressure, which may be due to its depressant effect on the sino-atrial node and sedative action.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.